Impact of Mirabegron Versus Solifenacin on Autonomic Function and Arterial Stiffness in Female Overactive Bladder Syndrome: a Randomized Controlled Trial

Overview

Journal Sci Rep

Specialty Science

Date 2022 Aug 20

PMID 35987885

Authors

Sheng-Mou Hsiao

Fung-Chao Tu

Ta-Chen Su

Pei-Chi Wu

Ho-Hsiung Lin

Affiliations

Soon will be listed here.

Abstract

The study aims to elucidate the impact of mirabegron versus solifenacin on autonomic function and peripheral arterial conditions in women with overactive bladder syndrome (OAB). All consecutive women with OAB were randomized to receive 12 weeks of mirabegron 25 mg or solifenacin 5 mg once per day. Heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, blood pressure, and heart rate were compared between the two groups. There were 87 women (mirabegron, n = 43; and solifenacin, n = 44) who completed 12-week treatment and underwent heart rate variability examination. Systolic blood pressure (median: - 4.5 to - 5.5 mmHg) and diastolic blood pressure (median: - 0.5 to - 3.5 mmHg) decreased after solifenacin treatment, and heart rate (median: + 2 bpm) increased after mirabegron treatment, despite of no between-group difference. In addition, posttreatment heart rate variability, cardio-ankle vascular index, and ankle-brachial pressure index did not differ compared with baseline; and there were no between-group differences. In conclusion, solifenacin might decrease blood pressure, and mirabegron might increase heart rate. Nonetheless, there were no significant impacts of 12-week mirabegron versus solifenacin treatment on autonomic function and arterial stiffness.

Citing Articles

Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design,....

Zhang X, Mao Y, Liu Y, Sun J, Sun J, Pan C Front Surg. 2024; 11:1372175.

PMID: 39252844 PMC: 11381383. DOI: 10.3389/fsurg.2024.1372175.

Possible Clinical Benefits of Cardio-Ankle Vascular Index Measurement in Urological Diseases.

Bulbul E, Ozilhan M, Sezer A, Yetisen M, Ilki F Vasc Health Risk Manag. 2023; 19:127-132.

PMID: 36923496 PMC: 10010130. DOI: 10.2147/VHRM.S384937.

References

Shirai K, Utino J, Otsuka K, Takata M . A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006; 13(2):101-7. DOI: 10.5551/jat.13.101. View

. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996; 93(5):1043-65. View

Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V . Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol. 2006; 13(6):692-8. DOI: 10.1111/j.1442-2042.2006.01387.x. View

Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O . Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015; 116(4):612-22. DOI: 10.1111/bju.13068. View

Haylen B, Ridder D, Freeman R, Swift S, Berghmans B, Lee J . An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2009; 21(1):5-26. DOI: 10.1007/s00192-009-0976-9. View

Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M . Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006; 68(2):318-23. DOI: 10.1016/j.urology.2006.02.042. View

Murabito J, Evans J, Larson M, Nieto K, Levy D, Wilson P . The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med. 2003; 163(16):1939-42. DOI: 10.1001/archinte.163.16.1939. View

Andersson K, Campeau L, Olshansky B . Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011; 72(2):186-96. PMC: 3162648. DOI: 10.1111/j.1365-2125.2010.03813.x. View

Wu W, Sheu B, Lin H . Comparison of 20-minute pad test versus 1-hour pad test in women with stress urinary incontinence. Urology. 2006; 68(4):764-8. DOI: 10.1016/j.urology.2006.04.018. View

10.

Drake M, MacDiarmid S, Chapple C, Esen A, Athanasiou S, Cambronero Santos J . Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). Int J Clin Pract. 2017; 71(5). PMC: 5485167. DOI: 10.1111/ijcp.12944. View

11.

Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z . Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2018; 38(1):22-30. DOI: 10.1002/nau.23863. View

12.

Maldonado J, Pereira T, Polonia J, Silva J, Morais J, Marques M . Arterial stiffness predicts cardiovascular outcome in a low-to-moderate cardiovascular risk population: the EDIVA (Estudo de DIstensibilidade VAscular) project. J Hypertens. 2011; 29(4):669-75. DOI: 10.1097/HJH.0b013e3283432063. View

13.

Rosa G, Baccino D, Valbusa A, Scala C, Barra F, Brunelli C . Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. Expert Opin Drug Saf. 2018; 17(5):487-497. DOI: 10.1080/14740338.2018.1453496. View

14.

Su T, Lin L, Baker D, Schnall P, Chen M, Hwang W . Elevated blood pressure, decreased heart rate variability and incomplete blood pressure recovery after a 12-hour night shift work. J Occup Health. 2008; 50(5):380-6. DOI: 10.1539/joh.l7056. View

15.

Chapple C, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N . Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Eur Urol. 2019; 77(1):119-128. DOI: 10.1016/j.eururo.2019.09.024. View

16.

Khurana S, Chacon I, Xie G, Yamada M, Wess J, Raufman J . Vasodilatory effects of cholinergic agonists are greatly diminished in aorta from M3R-/- mice. Eur J Pharmacol. 2004; 493(1-3):127-32. DOI: 10.1016/j.ejphar.2004.04.012. View

17.

Mo W, Michel M, Lee X, Kaumann A, Molenaar P . The β -adrenoceptor agonist mirabegron increases human atrial force through β -adrenoceptors: an indirect mechanism?. Br J Pharmacol. 2017; 174(16):2706-2715. PMC: 5522995. DOI: 10.1111/bph.13897. View

18.

Schiffers M, Sauermann P, Schurch B, Mehnert U . The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. World J Urol. 2010; 28(5):651-6. DOI: 10.1007/s00345-010-0513-y. View

19.

Scaldazza C, Morosetti C . Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Urol Int. 2016; 97(3):325-329. DOI: 10.1159/000445808. View

20.

Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T . Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011; 18(11):924-38. DOI: 10.5551/jat.7716. View